Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
The pharmacokinetic characteristics of azlocillin were compared in 7 children with cystic fibrosis (CF) and 6 children without this disease who were all treated for infectious diseases. Azlocillin was administered as intravenous bolus injections in doses of 200 mg/kg. The serum concentrations were somewhat lower in CF than in non-CF as reflected by total areas under the serum concentration curves of 594 and 677 mg h/1, and serum levels after 8 hrs of 10.7 mg/1 in non-CF vs. a concentration below the detection limit in CF. The CF children had a lower serum half-life (1.1 hrs) than the children without this disease (3.3 hrs). The difference is explained by higher total body clearance in CF (12.7 1/h) than the non-CF group (8.4 1/h). The dose interval should either be shorter, or the doses increased, when azlocillin is administered to patients with CF.
D000293:Adolescent; D001390:Azlocillin / Q000097:blood* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male
D001390:Azlocillin